Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Purification technology applicable to mass production of human-used avian influenza vaccine

A technology for avian influenza and avian influenza virus, applied in the direction of recovery/purification, medical preparations containing active ingredients, antibody medical ingredients, etc., can solve problems such as being easily affected by other conditions, uneven separation effects, and large batch-to-batch differences. Achieve the effect of low cost, small difference between batches, and simple process

Inactive Publication Date: 2010-01-27
DALIAN ALEPH BIOMEDICAL
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the purification results of newly installed chromatographic columns in large-scale production are different from those of chromatographic columns that have been used for a period of time, so the batch-to-batch difference is large, the operation is complicated, the time is long, the separation effect is not uniform, the yield is low, the cost is high, and it is easy to be affected by other methods. conditional influence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purification technology applicable to mass production of human-used avian influenza vaccine
  • Purification technology applicable to mass production of human-used avian influenza vaccine
  • Purification technology applicable to mass production of human-used avian influenza vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] 1. Materials and equipment

[0033] Viral allantoic fluid batch number: Q0601 Q0602 Q0603 Q0604

[0034] Liquid volume (L): 34.0 35.2 35.5 35.2

[0035] Hemagglutination titer: 1:1280 1:960 1:1280 1:1280

[0036] pH7.2PBS

[0037] 30% and 55% sucrose

[0038] 300 mesh filter cloth

[0039] Continuous flow centrifuge: model CR21G (Hitachi)

[0040] Ultrafiltration concentration system: 100KD membrane bag Millipore company

[0041] Ultracentrifuge: Model CP70MX Hitachi Corporation

[0042] Ultraviolet detector: model 8823A-UL, peristaltic pump.

[0043] 2. Method

[0044] Four batches of viral allantoic fluid with batch numbers Q0601, Q0602, Q0603, and Q0604 were filtered with 300-mesh filter cloth to remove insoluble impurities such as egg skin, and then centrifuged at 8000rpm in a continuous flow centrifuge to remove macromolecular substances. The virus liquid was concentrated 30-50 times by 100KD membrane ultrafilter, and then centrifuged at 30,000 rpm for 3 h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biotechnology and relates to the purification technology for avian influenza viruses, which is applicable to the mass production of human-used avian influenza vaccines. The purification technology is characterized in that: the avian influenza viruses are inoculated on a 9 to 11 days chicken embryo; the influenza viruses are cultured for 68 to 72 hours; and the allantoic fluid of the chicken embryo is sequentially collected, coarsely filtered, centrifugated with a continuous flow, ultrafiltered, condensed, centrifugated in a sucrose density gradient to be purified. The technology has the advantages of simple operation, small difference between batches, stable quality, high yield, low ovalbumin content and the like.

Description

technical field [0001] The technology belongs to the field of biopharmaceuticals. It relates to an avian influenza virus purification technology that can meet the large-scale production of human-used avian influenza split vaccine. Background technique [0002] Avian influenza virus is caused by type A influenza virus of the family Orthomyxoviridae, and it is an acute infectious disease of various poultry and wild birds. The disease is distributed globally and causes huge economic losses to the poultry industry. In 1997, a strain of avian influenza H5N1 virus was directly transmitted from birds to humans in Hong Kong, infecting 18 people and killing 6 people. This incident shows that avian influenza can cause human influenza epidemics. In recent years, bird flu has spread worldwide. Asia has been at the center of the world bird flu crisis in recent years. According to the analysis of relevant personnel, the threat of bird flu will continue for many years. Health experts w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/02A61K39/145A61P31/16
Inventor 闫昆明魏传忠王敏文王飞宇杨屹赵彬周蕾郭文军聂飞陈楠傅连弟李卫东
Owner DALIAN ALEPH BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com